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ABSTRACT 
Telomerase is a ribonucleoprotein enzyme. The catalytic and rate-limiting component of 
telomerase is referred to as telomerase reverse transcriptase (TERT) that plays an important 
role in telomere maintenance, cell immortalization and malignant transformation. Due to its 
aberrant expression and critical role in cancer development and progression, TERT has been 
suggested as a promising molecular marker for cancer diagnosis and prognosis. Thyroid 
cancer is the most common endocrine cancer. The diagnosis and treatment for thyroid cancer 
has been extensively studied; however, the molecular mechanisms underlying the roles of 
TERT in thyroid cancer are incompletely understood. The aim of this thesis was to explore 
the regulation, biological role and clinical significance of TERT in thyroid cancer. 
Somatic mutations of the TERT promoter, a genetic event for telomerase activation, were first 
described in malignant melanoma and have then been identified in various types of cancer 
during the last two years. The TERT promoter mutations were detected in follicular thyroid 
cell- derived thyroid carcinomas but not in parafollicular C cell-derived medullary thyroid 
carcinoma (MTC); the presence of the mutation was associated with shorter telomeres, poor 
outcome and aggressive clinical features. TERT promoter mutation was also found in 
follicular thyroid adenoma with uncertain malignant potential, which indicates that it is an 
early genetic event in thyroid carcinogenesis.  
Despite the absence of TERT promoter mutations, telomerase activation including TERT 
expression and telomerase activity was detected in more than half of MTCs, and associated 
with aggressive disease behavior and poor outcome. These results suggest that TERT can 
serve as a useful prognostic marker for MTC. It was further revealed that TERT copy number 
alterations, TERT promoter methylation, different TERT RNA splicing variants and other 
cancer-related proteins contributed to the up-regulation of TERT expression in MTC. Besides 
telomerase activation, alternative lengthening of telomere (ALT) was identified as another 
mechanism for telomere length maintenance in MTC. 
The known oncogenic RET and RAS mutations were also detected in MTCs; however, no 
association was found between these two genetic events and clinical features. The tyrosine 
kinase inhibitor vandetanib decreased MTC cell viability in in vitro experiments, but proteins 
regulated in response to the RET pathway inhibition need to be further clarified. 
In summary, this thesis provides further insights into the molecular mechanisms for 
telomerase activation and aberrant TERT induction, and the roles of TERT/telomerase in 
human thyroid carcinogenesis. More importantly, the findings underline the clinical 
importance of TERT/telomerase assessment in thyroid cancer. 
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1 INTRODUCTION 
1.1 CANCER AND ITS MOLECULAR GENETIC BACKGROUND 
1.1.1 Multi-step molecular genetic development of cancer 
Cancer arises from cells in normal human tissues that grow out of control and may invade 
adjacent and distant tissues. Cancer is a disease of genes, and the genetic instability that is 
characteristic of cancer drives the tumor development. Normal cells divide and die under the 
strict control of complicated molecular mechanisms, and they are able to mature into cells 
with well-differentiated phenotypes and specific cellular functions. Normal cells are also 
capable of eliminating or repairing genetic errors or mistakes that occur as they divide; 
otherwise they will launch the cell death program. However, cancer cells are able to keep the 
genetic errors or damages without dying and transfer them to their daughter cells. The 
accumulation of these molecular changes will prompt them to replicate uncontrolled, to 
acquire more and more genetic abnormalities, to break down the normal tissue, and to invade 
surrounding or distant tissues. An example of cancer development and progression is 
illustrated in Figure 1. The initiation and progression of cancer follow a Darwinian type of 
evolution, that generally takes decades of time and involves multiple genetic and epigenetic 
changes. Today we know that six biological capabilities are acquired during cancer 
development to conquer the barriers of cell death: evading of growth suppressors, sustaining 
of proliferative signaling, resistance to cell death, induction of angiogenesis, enabling of 
replicative immortality and activation of mechanisms for invasion and metastasis [1, 2]. 
 
Figure 1. The model of multi-step development of cancer. 
1.1.2 Genetic changes in cancer 
In the late nineteenth and early twentieth centuries, David von Hansemann and Theodor 
Boveri proposed that cancer is caused by abnormalities of hereditary materials, which was 
supported by the discovery of DNA and mutagens of cancer. During the last century, a large 
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body of cancer research has demonstrated that alterations of genes controlling cell 
proliferation and survival will lead to cancer. As shown in Figure 2, there are many types of 
genetic alterations for example gene mutations and numerical and structural alterations of 
chromosomes or chromosomal loci (loss or gain, chromosome rearrangement). The genetic 
abnormality is the consequence of one or combinations of these alterations.  
 
Figure 2. Examples of genetic alterations in human cancer. 
1.1.2.1 Gene mutations 
Mutations may result from exposure to different mutagens or by chance during cell division. 
Based on the DNA alteration and whether it alters the genetic code or not, mutations are 
categorized into different classes. Base substitutions where a single base is replaced are 
frequent, and can induce altered peptide sequence (non-synonymous mutation) affecting a 
single amino acid (missense mutation) or giving a shorter protein from a premature stop-
codon (non-sense mutation). A single base replacement that does not change the affected 
amino acid is called synonymous mutation. In addition, the mutation may involve addition or 
loss of base pairs where one or more nucleotides are either deleted from the gene (deletion 
mutation), or inserted into the sequence (insert mutation) and which may shift the reading 
frame (frame-shift mutation). Besides these common types of mutations, dynamic mutations 
of unstable genetic sequences also occur. Depending on the cell type in which the mutation 
occurs, they are classified as constitutional or somatic mutations. Both of them may cause 
cancer in the human body. 
1.1.2.1.1 Constitutional mutations 
In the case of constitutional mutations, the heritable information is altered by mutated gene 
alleles, which will be transmitted by germ cells from parents to offspring. This type of 
mutation, which is present in all the cells of the body, is either inherited from a parent or has 
occurred de novo and can be passed from generation to generation. Around 5% to 10% of 
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human cancers are induced by a constitutional mutation, which is referred to as familial 
cancer. Multiple endocrine neoplasia type 2 (MEN 2) with familiar occurrence of medullary 
thyroid carcinoma (MTC) and other endocrine tumors is a good example of inherited cancer 
predisposition caused by a constitutional mutation. 
1.1.2.1.2 Somatic mutations 
Somatic mutations occur in single somatic cells, which will affect the phenotype of the cell. 
They may be acquired after exposure to mutagens in the environment or surrounding cellular 
microenvironment or they may occur by coincidence. Somatic mutations can be passed to the 
descendant cells within the same tissue, but not to the offspring. Most human cancers have 
been shown to carry cancer-related somatic mutations, and these mutations play a central role 
in the development of cancer.  
1.1.2.2 Chromosomal aberrations 
As early as in 1914, chromosomes abnormality in cancer cells were observed by light 
microscopy [3]; hence they are referred to as large-scaled alterations. Similar to the small-
scaled alterations in cancer cells, chromosomal abnormalities may occur on the somatic or 
constitutional level. Alterations involving the structure and number of chromosomes are the 
main categories of chromosomal aberrations in human cancer.  
1.1.2.2.1 Structural abnormalities 
Eukaryotic chromosomes consist of three DNA sequence elements: DNA replication 
elements, telomeres and centromeres. During the cell cycles, the chromosome structure 
displays quite different appearances. The prometaphase and metaphase chromosome has two 
chromatids, while in the interphase the chromosome shows a single chromatid and DNA 
double helix structure. 
Structural aberrations can be induced by DNA damage or DNA recombination. Chromosome 
breaks that occur in a single chromosome following DNA damage can lead to insertion, 
deletion, inversion, duplication, ring chromosome or gene rearrangements; breaks in two 
chromosomes trigger chromosomal translocations. The abnormal chromosome structure may 
affect genes that are crucial for cancer development, leading to activation, over-expression or 
inactivation. .  
1.1.2.2.2 Numerical abnormalities 
The normal chromosomal composition is a euploid karyotype, however, aneuploidy is 
frequently observed in cancer cells. The acquiring of extra copies of chromosomes or the loss 
of a chromosome copy can benefit the cancer cells and prompt its uncontrolled growth. 
1.1.3 Epigenetic changes in cancer 
The term epigenetics refer to heritable changes in cells that do not affect the underlying DNA 
sequences. Epigenetic mechanisms are crucial for gene expression in human cells and are 
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essential for the normal cell development and differentiation. Thus, epigenetic studies are 
expected to contribute to the understanding of differences in morphology and function 
between cells that carry the same DNA sequence. The epigenetic modifications can either 
activate or inhibit gene expression. Researches over the past decades have highlighted the 
important role of epigenetic dysregulations in the initiation and progression of human cancer. 
DNA methylation, histone modification, and RNA-mediated gene expression regulation are 
three main epigenetic systems involved in gene regulation. 
1.1.3.1 DNA methylation 
DNA methylation was proposed to regulate gene expression during cell development and 
differentiation in 1975 [4, 5]. Since then, plenty of research has proved that DNA methylation 
is essential in regulation of gene expression in normal cells and cancer [6-13]. Generally, 
DNA methylation occurs in cytosine guanine dinucleotides, which are distributed in clusters 
commonly known as CpG islands. The methylation can induce covalent binding of a methyl 
group to the C-5 position of a CpG dinucleotide. The CpG-rich areas span the regulatory 
region of many genes at the 5´ end [14]. In normal cells, these CpG islands are commonly un-
methylated or have a very low level of methylation [15]. By contrast in most tumor cells 
altered methylation levels may be observed in promoter regions [16, 17]. 
Altered methylation involves DNA hypomethylation and hypermethylation, and both are 
known to contribute to cancer cell development [18-20]. CpG islands at the gene promoter 
region are seldomly methylated under normal conditions, but are frequently found to be 
hypermethylated or hypomethylated in different types of cancer. Hypermethylation in the 
promoter region of tumor suppressor genes (TSGs) is the major epigenetic event in cancers 
known today. Inactivation of TSGs by promoter hypermethylation is illustrated in Figure 3. 
In the classical situation this will inactive TSGs through reduced expression with 
consequences for various cell regulations. Therefore, methylation of CpG islands was 
considered as one of the hallmarks of cancer [21, 22]. The increasingly noted 
hypomethylation at repetitive sequences, coding sequences and introns associated with tumor 
progression is less clarified [23, 24]. Loss of methylation may facilitate for deletions and 
translocations to occur and thus increase the frequency of chromosomal instability [18, 25]; it 
can also disrupt the genomic imprinting and thereby increase the risk of cancer [26].  
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Figure 3. Tumor suppressor gene suppression by DNA hypermethylation. 
1.1.3.2 Histone modification 
In eukaryotic cell nuclei, the DNA molecule is organized in nucleosomes by a highly alkaline 
protein called histone. The five known histone family proteins are the main functional 
proteins in chromatin. Histone 1 and histone 5 are linker proteins, and histone 2, 3 and 4 are 
core assembly proteins of the nucleosome. Within the chromatin, DNA is twisted around the 
histones; hence, histones work as spools in chromatin. Histones can also be involved in gene 
regulation including gene activation and repression. The amino acids on the long histone tail 
can be covalently modified, thereby inducing interactions with DNA and with other nuclear 
proteins. Several different types of histone modifications are known such as acetylation, 
methylation, ubiquitination, and phosphorylation. Methylation and acetylation play a role in 
DNA replication, transcription regulation and DNA repair. The methylation of certain histone 
residues are related to different biological processes. Histone modifications are known to 
contribute to the development of cancer in different organs [27-29]. 
1.1.3.3 RNA-mediated gene regulation 
During the last two decades, the increasing knowledge of RNA molecules has expanded the 
understanding of gene regulation in cancer dramatically. This is especially evident for the 
research following the discovery of microRNA in 1993 [30]. MicroRNAs are short, small, 
around 22-nucleotide non-coding RNAs. Its special sequence can imperfectly complement 
with the 3´ un-translated region ( 3´-UTR) of target mRNAs, thereby inducing translational 
repression [31]. Research on microRNA expression in cancer has revealed that expression 
differs between tumor and normal tissue, and the down-regulation of certain microRNAs has 
important roles in gene regulation in cancer [32-34]. The regulation of microRNAs may 
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involve the microRNAs processing machinery or epigenetic mechanisms. The translational 
silencing by non-coding RNAs has therefore been considered as one type of epigenetic 
mechanism for gene regulation [35-37]. 
1.1.4 Important genes involved in cancer 
Human cancer commonly exhibits multiple chromosomal alterations and mutations. Three 
main types of genes play a crucial role in tumorigenesis and contribute to cancer formation 
and development: oncogenes, tumor suppressor genes and DNA repair genes. 
1.1.4.1 Proto-oncogenes 
Proto-oncogenes are growth-controlling genes in normal human cells, which were discovered 
by retrovirologists in the 1970s. They usually participate in the receiving, transducing and 
processing of growth or proliferation signals to cells. A proto-oncogene may turn into a 
cancer-causing oncogene if it is altered in certain ways, such as by genetic alterations 
affecting the protein structure or expression. Examples of such underlying genetic alterations 
are chromosomal rearrangements giving new regulatory elements or fusion genes, and 
activating mutations. These changes will release signals to stimulate the cells to proliferate 
out of control. Mutated RET and RAS genes are well known oncogenes in human cancers. 
1.1.4.2 Tumor suppressor genes 
Tumor suppressor genes (TSGs) are involved in the government of dynamic cell proliferation 
coupled with proto-oncogenes, and regulate cell proliferation via different mechanisms. 
Inactivation of TSGs will disrupt the control of cell proliferation and has been observed more 
frequently in cancer than activation of oncogenes. The normal function of a TSG may be lost 
by several different mechanisms: loss of heterozygosity (LOH), genetic mutations and 
epigenetic silencing are the most commonly observed. Inactivation of the TSG TP53 is seen 
in the majority of human cancers. 
1.1.4.3 DNA repair genes 
The normal systems for genome maintenance provide another important barrier to cancer, 
and deficiencies in these systems contribute to cancer development. Nucleotide repair, 
mismatch repair, homologous recombination, end joining and telomere maintenance are 
important biological mechanisms for genome stability. 
1.2 THE HUMAN THYROID GLAND AND THYROID TUMORS 
1.2.1 The thyroid gland and its physiological function 
The thyroid gland is located in front of and surrounding the trachea in the neck. As shown in 
Figure 4, the thyroid gland consists of two lobes connected by the isthmus in the middle. The 
cellular composition includes a majority of follicular cells (thyrocytes), parafollicular 
calcitonin-producing C-cells, endothelial cells, fibroblasts and lymphocytes [38].  
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Figure 4. Anatomy of the thyroid gland and its physiological functions. 
The basic structural and functional component of the thyroid gland is termed follicle (Figure 
4). The follicle is surrounded by a single layer of thyroid follicular epithelial cells in which 
hormone is synthesized and stored. The follicle content is termed colloid, containing mature 
thyroglobulin and thyroid hormone in the form of triiodothyronine (T3) and thyronine (T4), 
which are synthesized and secreted by the follicular cells. The follicular cells absorb iodide 
from the blood, and then release it to the colloid where it is oxidized to iodine and binds to 
proteins such as thyroglobulin. The protein complex is then reabsorbed and undergoes 
proteolysis in follicular cells. Finally, T4, but also some T3, is released to the blood stream. 
T4 is peripherally de-iodonized to T3, which is the active form of thyroid hormone. The 
synthesis and secretion of thyroid hormones is subject to negative feedback regulation of the 
hypothalamin-pituitary-thyroid axis. Briefly, thyrotropin-releasing hormone (TRH), produced 
by hypothalamus, binds to receptors on the pituitary and stimulates the release of thyroid 
stimulating hormone (TSH). TSH receptors (TSHR) on thyroid follicular cells initiate the 
synthesis of thyroid hormones. In contrast, high concentration of T3 will inhibit the release of 
TRH and TSH, preventing the further production of thyroid hormone [39]. 
The thyroid plays an essential role in cell metabolism, growth and development via binding 
of thyroid hormone to thyroid hormone receptors in the cell nuclei. Calcitonin, produced by 
parafollicular C-cells, regulates calcium homeostasis in the human body. Thyroid dysfunction 
will cause increased or decreased thyroid hormone levels, inducing either hyperthyroidism or 
hypothyroidism, respectively. 
1.2.2 Thyroid tumors 
Thyroid tumors are classified into two main categories: adenomas and carcinomas. Follicular 
thyroid adenoma is the only benign thyroid tumor. Carcinomas can be grouped according to 
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their cellular origin, degree of differentiation and histopathological features. Adenomas are 
common in all populations all over the world, especially in parts of Europe, North America 
and Australia. Thyroid carcinomas are less common. It accounts for approximately 1% of all 
malignancies registered, but comprises 80% of all endocrine malignancies. 
1.2.2.1 Follicular thyroid adenoma (FTA) and atypical thyroid adenoma (AFTA) 
FTA is a common, follicular cell-derived thyroid tumor. The incidence is higher in women 
than in men. It can be described as a solid, round or oval, homogeneous tumor which is 
surrounded by a thin capsule. Adenoma cells can form regular follicles or a trabecular 
pattern; however, the tumor capsule and vessels are not invaded by tumor cells. The 
cytological pre-operative examination by fine-needle aspiration (FNA) cannot safely 
distinguish FTA from carcinomas since mitoses and pleomorphic changes may be 
overlapping features between these two entities [40, 41]. Once the patient is diagnosed with a 
thyroid follicular tumor by FNA cytology, lobectomy should be performed to further 
establish the diagnosis [42]. Provided no signs of malignancy are found by the 
histopathological examination, lobectomy alone is sufficient as the final treatment. This 
histopathological examination therefore includes a complete tumor capsule without any 
tumor in-growth, and lack of vessel invasion.  
Follicular adenomas with high cellularity, abnormal nuclei, unusual histologic features and 
suspicious malignant potential are referred to as atypical follicular thyroid adenoma (AFTA). 
This specific entity is regarded as having an uncertain malignant potential. Besides AFTA, 
many variants of FTA have been recognized [40]. 
1.2.2.2 Medullary thyroid carcinoma (MTC) 
MTC, arising from the parafollicular calcitonin-producing C- cells, is a differentiated form of 
thyroid carcinoma that accounts for 5-8% of human thyroid cancers. The C-cells are located 
at the basal layer of the thyroid follicles, and account for 1% of all thyroid cells. During fetal 
development, C-cells immigrate from the neural crest; hence, MTC is referred to as a 
neuroendocrine tumor. Approximately 75% of the cases are sporadic and the remaining 25% 
are parts of the autosomal dominant multiple endocrine neoplasia type 2 (MEN 2) syndrome 
[43]. MEN 2A is characterized by MTC, pheochromocytoma and primary 
hyperparathyroidism; MEN 2B is characterized by MTC, pheochromocytoma, 
ganglioneuroma and other phenotypes [44, 45]. The vast majority of MEN 2 patients carry a 
constitutional mutation of the RET (Rearranged during Transfection) proto-oncogene, but 
RET mutations also play an important role in sporadic MTC development. MTC usually 
occurs in the middle of the thyroid lobe where C-cells are located. It is a solid carcinoma 
causing increased calcitonin levels in serum.  
Histopathologically, MTC exhibits sheets, nests or trabecular spindles, round or polygonal 
cells and is surrounded by a vascular fibrous stroma. Most MTCs are strongly positive for 
calcitonin staining. MTC tends to metastasize to lymph nodes, especially the cervical lymph 
nodes at an early stage. Distant metastases are frequently found in liver, bone and lung [40]. 
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The initial treatment for MTC is total thyroidectomy plus lymph node dissection in the neck 
[46]. The calcitonin level in serum is an important prognostic marker; increased calcitonin 
post-operatively indicates persistent diseases, and further treatment or surveillance could be 
indicated. Recurrence is seen in 5-12% of patients several years after the first operation [47]. 
Presence of a somatic RET mutation, age, gender and distant metastases are risk factors 
affecting the survival of MTC patients [48]. 
1.2.2.3 Follicular cell-derived human thyroid carcinoma 
Thyroid carcinoma originating from follicular cells consists of two well differentiated types: 
follicular thyroid carcinoma (FTC) and papillary thyroid carcinoma (PTC). The poorly 
differentiated thyroid carcinoma (PDTC) and undifferentiated, or anaplastic thyroid 
carcinoma (ATC) may be the result of a stepwise dedifferentiating process from PTC or FTC, 
but may also arise de novo. 
1.2.2.3.1 FTC 
FTC accounts for 15-20% of all malignant thyroid tumors and it is the malignant counterpart 
of FTA and AFTA. FTCs are differentiated solitary tumors that can be more or less 
encapsulated. They typically occur in women at their 50s but one third occur in men. The 
histopathological features of FTC are hyper-cellularity, differentiated follicular cells, invasion 
of blood vessel and capsule but without the specific characteristics of PTC [40]. Depending 
on the degree of invasiveness, FTC can be sub-classified as minimally invasive and wildly 
invasive type. The latter can cause disruption of the tumor capsule and invade surrounding 
thyroid tissue, thus leads to less favorable prognosis. Metastases are found in the bone, lung 
and liver, but are rare in the brain [49, 50].  
Oxyphilic cell type (Hürthle cell type) carcinoma is a variant of FTC. It accounts for 3-4% of 
thyroid cancer, and appears as a solitary tumor with large nuclei and plenty of mitochondria 
in the cytoplasm [40, 51].  
1.2.2.3.2 PTC 
PTC is the most common type of thyroid cancer (80-85%) that frequently occurs in women 
(75%), typically around menopause. The development of PTC is influenced by environmental 
factors such as radiation exposure, especially in children. The incidence of PTC increased 
rapidly in young people after the Chornobyl nuclear plant accident in Ukraine [52]. PTCs are 
differentiated thyroid carcinomas that appear as firm nodules without regular and clear 
borders; invasion to surrounding thyroid tissue may be observed. The microscopic picture has 
characteristic features including hyper-cellularity, enlarged nuclear, ground-glass appearing 
nuclei, grooves in nuclear contours and psammoma bodies in the tumor cell stroma or in 
lymphatic spaces [40, 51]. Patients with PTC usually undergo total thyroidectomy followed 
by radioiodine ablation. The overall prognosis for PTC patients is excellent, and is better than 
for other types of thyroid cancer [51, 53].  
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There are several variants of PTC such as follicular-variant PTC, tall cell PTC as well as a 
few rare variants. 
1.2.2.3.3 PDTC 
PDTC originates from follicular cells, but its morphology and behavior suggest that it is an 
intermediate form between differentiated carcinoma and ATC. PDTCs are solitary large 
tumors with various histopathologic features, including insular, trabecular and solid patterns. 
Infiltration to surrounding tissues and vessels and distant metastases are frequently observed. 
The prognosis for PDTC patients is much less favorable than for PTC and FTC [40, 51].  
1.2.2.3.4 ATC 
ATC is a rare, highly malignant form of thyroid tumor characterized by undifferentiated cells. 
ATCs are large, often infiltrating surrounding tissues and disrupting the structure of the 
normal thyroid. At diagnosis, they have commonly metastasized to regional lymph nodes and 
other organs. Histopathologically, ATC exhibits spindle cells and giant cells with multiple 
nuclei. Mitoses and necrosis are often seen [40]. The prognosis for ATC is dismal, and most 
ATC patients die within six months after diagnosis. Radiation combined with chemotherapy 
is used as palliation to improve the outcome of surgery [54, 55].  
1.2.3 Genetic alterations in thyroid tumor development 
1.2.3.1 Molecular genetic background of MTC 
The development of sporadic and MEN 2 associated MTC is strongly linked to activating 
mutations of the RET proto-oncogene, which was identified by in vitro transfection with T-
cell lymphoma DNA. The RET gene is located in chromosomal region 10q11.2 and 
comprises 21 exons [56, 57]. The encoded receptor tyrosine-kinase functions as a membrane 
receptor for glial-derived neurotrophic factor family (GDNF) ligands. It is critical for the 
development of sympathetic, parasympathetic and enteric neurons, the kidneys, germ cells 
and thyroid C-cells [58]. The protein has three domains: the extracellular ligand-binding 
domain with cadherin-like repeats and a cysteine-rich region, the trans-membrane domain, 
and the tyrosine kinase domain. As a signaling receptor, it binds to the GDNF family via 
GDNF-family receptor-α (GFR-α), leading to phosphorylation of RET tyrosine residues [59]. 
The downstream cellular signaling initiated by GDNF ligands can activate RET via two 
different mechanisms: cis- and trans-activation; which in turn will activate different 
downstream kinases [58]. 
Most cases of MEN 2 are caused by a constitutional RET mutation. RET was identified as the 
predisposing gene for MEN 2 in the 1990s by genetic linkage analyses in affected families 
[60, 61]. Point mutations in exon10 and exon11 are the most common causes of MEN 2A; 
the majority of MEN 2B is caused by a mutation in exon 16 (Met 918 Thr) which has often 
occurred de novo, and a few cases are caused by mutations at other codons for example 883 
and 806 [62-65]. Approximately 40% of sporadic MTC cases have a somatic RET mutation 
in exon 16, and the M918T mutation is the predominant type. All RET mutations in MTC 
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lead to gain-of-function of the RET protein, among which the M918T mutation induces 
multiple down-stream signaling changes. On the one hand, M918T mutation allows the 
tyrosine kinase to be stimulated without ligand binding; on the other hand, RET substrates 
can be modified by the M918T mutation [58]. The M918T mutation has been associated with 
a poor outcome in patients with MTC [66, 67]. Besides RET point mutations, a translocation 
involving RET intron 12 was revealed in one female patient, and the RET fusion has been 
identified as oncogenic driver in sporadic MTC in vitro [68].  
RAS mutation is another oncogenic event in MTC, which was first reported in 2011 [69]. RAS 
genes, including HRAS, KRAS and NRAS, are the most commonly mutated proto-oncogenes 
in human cancers. They encode approximately 21 kDa RAS proteins, that play an important 
role in transducing signals from the cell surface [70]. Activating mutations of the RAS 
oncogene have been thoroughly described in different kinds of tumors, and have also been 
established in follicular cell-derived thyroid cancer. The presence of different RAS mutations 
and their clinical implications in sporadic MTC have been reported in previous studies [71, 
72]. 
1.2.3.2 Genetic alterations in other types of thyroid tumors 
The most common genetic aberrations in PTC are BRAF (v-Raf murine sarcoma viral 
oncogene homolog B1) mutations and different chromosomal rearrangements. The BRAF 
gene in chromosomal region 7q34 encodes a protein that belongs to the serine/threonine 
kinase family, which is known to play a role in cancer development. The V600E substitution 
at position 1799 is frequently detected in PTC, and it has been identified as a prognostic 
marker for PTC; in addition, the BRAF mutation is also present in ATC (25%) and PDTC 
(20-40%) [73].  
Several chromosomal rearrangements including the RET gene have been identified in PTC, 
and are thus termed RET/PTC. The para-centric inversion of chromosome 10 leads to RET 
fusions with other genes and subsequent activation of RET signaling pathways; RET/PTC 
fusion oncogenes are important genetic events in PTC development [74].  
RAS mutation is a common genetic event in FTC and ATC [51]. The occurrence of RAS 
mutation in FTA, FTC and ATC suggests a role for RAS in tumor progression [75]. It is also 
detected in PDTC and FVPDC [51, 76]. 
The paired box 8 (PAX8) - peroxisome proliferator activated receptor γ (PPARγ) fusion is the 
outcome of the translocation t (2; 3) (q13; p25). This gene fusion is frequently observed in 
FTC (60%) and is considered as a specific marker for FTC; however, it has also been 
reported in FTA [77, 78]. 
In addition, copy number gains of proto-oncogenes in the PI3K-AKT pathway, promoter 
mutation and promoter methylation of TERT [79] as well as mutation and promoter 
methylation of TSGs are also involved in thyroid tumor development [51]. 
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1.3 TELOMERE AND TELOMERASE 
The semi-conservative DNA replication is initiated in the 5´-to -3´ direction by the RNA 
primer and DNA polymerase, and continues until the linear end of the chromosome in 
eukaryotic cells. The 5´gap in a newly synthesized daughter chromosome cannot be filled; 
therefore, chromosome ends become shorter after each successful replication. Nevertheless, 
the entire genetic information in the chromosomes is replicated in normal eukaryotic cells and 
chromosomes remain stable without fusing end-to- end. The reason for this phenomenon is 
the tandemly repeated sequences called telomeres that are present at the chromosome ends. 
Telomeres thus serve as protective shields for the chromosomes in eukaryotes. Telomeres are 
synthesized by a ribonucleoprotein enzyme called telomerase, which can polymerize 
nucleotides into tandem repeats of telomeric DNA sequence at the end of each chromosome. 
Telomeres and telomerase exhibit alterations in many diseases including cancer, which are of 
biological and clinical significance, especially in cancer. In this thesis, the telomere 
maintenance, TERT dysregulation, telomerase reactivation and their clinical implications in 
thyroid tumors were explored. 
1.3.1 Telomere 
1.3.1.1 Its discovery and structure 
In the 1930s, Muller created the term "telomere", and suggested that it is a special structure at 
the end of chromosomes [80]. Then in the 1940s, Barbara McClintock reported that 
chromosomes fused to each other after losing the special structure at chromosome ends in 
corn [81-83]. This discovery together with her pioneering work on transposons in corn 
brought her the Nobel Prize in 1983. In 1978, Elizabeth Blackburn revealed that TTGGGG 
sequences are tandemly repeated at chromosome ends in Tetrahymena thermophile [84].  
Telomere, a complex of DNA and protein, is conserved on telomeric DNA in different 
eukaryotes. The telomere sequences consist of a double stranded DNA repeat sequence 
(TTAGGG in human), which are short and rich in G-residues on the 5´ to 3´ strand running 
towards the end of the chromosome [85]. This G–rich strand protrudes the duplex and forms 
a single stranded G-rich overhang termed G-tail [86]. In the S-phase of the cell cycle, the G-
tail increases and the 3´ overhangs usually invade and insert into the double stranded 
telomere repeats to form a t-loop [87], and thus play a role in the telomere maintenance. The 
length of the telomeric repeat sequences varies between species, and also in relation to age 
and disease. 
The proteins in the telomere complex can be divided into two categories: proteins directly 
binding to telomeric DNA and proteins interacting with binding proteins. In humans, the 
most important binding protein component is shelterin. Shelterin is a six protein complex 
consisting of TTAGGG repeat binding protein factor 1 (TRF1), TRF2, TIN2, Rap1, TPP1 
and POT1. The duplex of telomere is bound with TRF1, TRF2 and POT1, which interacts 
with Rap1, TPP1 and TIN2. The shelterin complex forms a special structure with the 
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telomere, for capping and protecting the telomere, and maintaining the chromosome structure 
[88]. 
1.3.1.2 Telomere replication 
The double stranded telomeric DNA is commonly replicated by the conventional DNA 
polymerase in each cell cycle. On the leading strand, the telomere can be replicated without 
loss of nucleotides. However, because of the cleavage of RNA primers, the telomere will lose 
a few nucleotides on the lagging strand. Telomerase can counteract the problem by 
polymerizing nucleotides into tandem repeats in the G-rich strand of the telomere. The G-tail 
at the blunt end of the telomere on the newly synthesized strand can be generated by C-strand 
degradation and telomerase-mediated elongation [89, 90]. 
1.3.1.3 Telomere function 
Telomeres and their DNA-protein complex structures protect chromosome ends from end-to-
end fusions, double-strand breaks and degradation. Besides maintaining the integrity of the 
chromosome, the telomere plays an essential role in life-span controlling of cells: the eroded 
telomere can induce permanent growth arrest (referred to as replicative senescence) and thus 
prevent cellular immortality [91, 92]. Telomere also participates into the process of 
chromosome positioning in the nucleus, heterochromatin formation and transcriptional 
repression in certain organisms [80].  
1.3.1.4 Maintenance of telomere length 
The telomere length is maintained by the balance between shortening and lengthening 
mechanisms, therefore the telomere structure and length are dynamic, not static in many 
organisms [93-97]. Several biological processes mediate the maintenance of telomere length 
that is affected in different diseases, including cancer. Telomerase-mediated elongation is the 
predominant pathway in humans; however additional mechanisms have been identified in 
other eukaryotes.  
Alternative lengthening of telomeres (ALT) is a telomerase-independent mechanism 
observed in human tumors and immortalized cell lines. Recombination-mediated DNA 
replication has been considered as the main mechanism for ALT. It involves a rolling-like 
spreading of replication using circular telomeric DNA produced by homologous 
recombination. Telomeres on the sister chromatids can be used as template for elongation in 
the T-loop configuration [98, 99]. 
Cells with involvement of the ALT pathway are characterized by heterogeneous length of 
telomeres and nuclear DNA-protein complex which is referred to as ALT-associated 
promyelocytic leukemia (PML) protein nuclear bodies (APBs) [100]. The PML gene is 
identified in acute promyelocytic leukemia [101]. The PML protein has been proved to be 
involved in different biological processes in different studies, such as cell apoptosis 
pathways, gene transcription regulation, DNA repair pathways as well as the chromatin 
remodeling [102-106]. In addition, telomeric DNA and telomere-binding proteins as well as 
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proteins related to DNA replication and homologous recombination are also found in 
APBs[99].  
Telomere binding proteins and DNA damage response proteins also play a role in telomere 
maintenance. In human, TRF1 can negatively regulate the telomere length by affecting 
telomerase. Rap1, binding to the telomere duplex, plays a role in telomere length regulation 
[107, 108]. 
1.3.2 Telomerase 
1.3.2.1 Discovery and its expression in vivo 
Telomerase was identified as a catalytic unit to extend telomeric sequences in Tetrahymena in 
1985 by Elizabeth Blackburn and Carol Greider [109]. Soon after they discovered the 
ribonucleoprotein complex consisting of two distinct components, possessing the terminal 
transcriptase activity[110], and the RNA component was identified as the template for 
telomeric DNA repeats synthesis in the complex [111]. The discovery of telomerase brought 
Carol W. Greider, Elizabeth Blackburn and Jack W. Szostak the Nobel Prize in 2009. 
In humans, the catalytic subunit for the synthesis of six nucleotides to the telomeric DNA is 
termed human telomerase reverse transcriptase (hTERT); the telomerase related RNA 
template is called hTR. The hTR is a 451 nucleotide non-coding RNA transcribed from 
TERC. The core region of hTR bearing nucleotide (5´-CUAACCCUAAC-3´) is 
complementary to the G-rich tail of the telomere [112]. The telomerase complex has other 
components besides TERT and the RNA template, for example dyskerin [113]. Several other 
proteins interact with telomerase which are involved in the trafficking, recruitment to 
telomere, telomerase biogenesis and degradation. However, they are not used as integral 
components of the holoenzyme and catalytic subunit [114]. 
Telomerase activity is detectable in 85% to 90% of human tumor tissues and cell lines. In 
addition, it is also present in early embryogenesis, testicular germ cells, stem cells and 
activated lymphocytes [115, 116]. In most normal somatic cells, telomerase is undetectable or 
present at very low levels; and the absence or a low level of telomerase activity cannot 
prevent progressive telomere erosion in normal cells. hTR is constitutively expressed in 
human cells, even in pre-crisis cells without detectable telomerase activity, whereas TERT is 
only expressed in cells with detectable telomerase activity. In addition, introduction of TERT 
into human normal fibroblasts induced telomerase activity, telomere elongation, sustained 
proliferation and reduced senescence, indicating that TERT is the rate-limiting subunit of the 
telomerase holoenzyme [112, 117-119]. 
1.3.2.2 Telomerase and its biological role in tumorigenesis 
Normal cells have a finite lifespan because of the erosion of telomeres in each cell cycle. 
After undergoing a limited number of cell cycles, cells with short telomeres will reach their 
Hayflick limits [120], then finally enter into senescence or crisis. Hence, depletion of 
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telomeres is a barrier to cell immortality. Cancer cells need to acquire the capability of 
unlimited replication and division by maintaining the telomere length. Telomerase, repressed 
in normal cells, is functionally reactivated in the vast majority of human cancers and 
immortal cells [118, 121]. On the one hand, expression of telomerase alone is sufficient for 
the cell escaping from crisis and immortalization; one the other hand, expression of 
telomerase can cooperate with oncogenes or inactivated TSGs, permitting tumorigenesis 
[122].Taken together, telomerase activation has an important implication for diagnostic and 
therapeutic applications, and has been considered an important clinical biomarker for 
different types of tumors. An attractive strategy for anti-cancer therapy is the usage of 
telomerase inhibitors to prevent restoration of the telomeres and thus induce cell death [123-
125].  
In recent years, multiple studies have demonstrated that the function of telomerase is not only 
limited to telomere maintenance, but also to cell proliferation independent of telomere 
maintenance. Telomerase/TERT functions independent of telomere maintenance are observed 
in conditions where the telomerase enzymatic activity has been eliminated [126].The non-
canonical roles of telomerase, and in particular its catalytic subunit TERT, have been 
revealed bearing functions related to the chromatin remodeling. For example, TERT serves as 
a co-factor of the β-catenin/LEF transcription factor complex, inducing amplification of the 
Wnt signaling pathway [127]. Other telomere lengthening-independent functions include 
involvement in RNA-dependent RNA polymerase function [128], and DNA-damage repair 
[129]. The contributions of these additional functions of telomerase to tumorigenesis remain 
to be fully elucidated. 
In summary, the telomerase complex facilitates the capping of chromosome ends via 
telomeres, so telomere maintenance is the most prominent of a diverse series of functions to 
which TERT contributes. The function of telomerase in keeping chromosome integrity, 
promoting cell immortality, and telomere-independent functions confer the tumor 
development and progression. 
1.4 REGULATION OF TELOMERASE IN HUMAN CANCER 
Attributing to its role in telomere maintenance and tumor formation, telomerase has been 
recognized as the crucial factor in oncogenesis. TERT as rate-limiting catalytic protein is the 
core subunit of telomerase holoenzyme. Its expression is positively correlated with 
telomerase activity, and thus its regulation in human cells has been extensively explored. 
TERT/telomerase expression can be regulated at various levels, including genetic, 
transcriptional, post-transcriptional and epigenetic levels, and by post-translational 
modifications, which will be described briefly below. 
1.4.1 Genetic aberrations of TERT in human cancer 
The human TERT gene, consisting of 16 exons and 15 introns, presents as a single copy gene 
located in chromosomal region 5p15.33, and extends over 40kb [130-133]. As shown in 
Figure 5, the proximal TERT promoter was identified within the region from 300 bp 
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upstream of the translation starting site (ATG) to the 37 bp of exon 2 [132]. Within this 
region, several transcriptional binding sites are identified, such as E-box and GC- box 
(described in detail below). 
 
Figure 5. Illustration of point mutations and methylation in the TERT promoter region. 
1.4.1.1 Copy number alterations 
Copy number gains of the TERT gene locus are frequently observed in various human cancer 
tissues and cancer cell lines [134], which may due to the increased whole chromosome 
number or copy number gain of the TERT gene locus. Chromosome 5p, the location of TERT 
gene, is frequent gained in tumors [135]. In previous studies, the chromosome 5p was shown 
to be amplified in many types of tumors [136, 137]. Taken together, TERT copy number 
gains are common in primary tumor tissues and cancer cell lines, and associated with 
increased telomerase activity [138]. It is therefore considered as one of several reasons for 
telomerase activation. 
1.4.1.2 TERT promoter mutation 
Besides TERT copy number gains, point mutation of TERT is another genetic feature of 
cancer. The TERT promoter mutation was first reported in human melanoma in 2013 [139, 
140]. As illustrated in Figure 5, two exclusive cytidine to thymidine (C > T) mutations 
locating at -124 and -146 bp from the ATG site are referred to as C228T and C250T 
mutation, respectively. These mutations create a new E26 transformation-specific (ETS) 
binding motif (5´- CCCCTTCCGGG-3´), stimulating TERT transcription [139, 141]. In 
addition to C228T and C250T, other mutations occur at low frequencies in this regulatory 
region, such as the CC > TT tandem mutations at -124/125 and -138/-139, the C > T mutation 
at -57. All these mutations promote the TERT transcription by creating new transcriptional 
factor binding sites [140]. 
These novel finding has inspired research on promoter mutation-induced TERT/telomerase 
up-regulation, which led to the discovery of frequent TERT mutations in other types of 
human cancers and immortal cell lines [79, 141-149]. Although mutation frequencies vary 
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among cancer types, endocrine tumors, hepatocellular cancers, renal pelvic cancers, gliomas, 
glioblastomas and skin cancers show high frequencies of TERT promoter mutations [146].  
In some studies, the mutation was found to be associated with increased TERT expression; 
however, in other studies, no consensus was reached. The TERT promoter mutation has been 
shown to correlated with different clinical features, such as tumor progression and patient 
survival in various cancer types [150-153]; the importance of these findings is reinforced by 
the growing list of human cancers showing clinical associations with TERT promoter 
mutations. 
C228T mutation is the major TERT promoter mutation in different types of thyroid tumors, 
but it is not present in normal thyroid tissues. The clinical implications of TERT promoter 
mutations have been explored in several studies. Undifferentiated thyroid cancer so called 
ATC displays the highest frequency of mutations (33-50%), PDTC shows a lower frequency 
than ATC but still higher than other types (29%); TERT promoter mutations in FTC (14-
36%) is comparable to PTC (8-25%). TERT promoter mutations have also been detected in 
AFTA and in a single case of FTA [79, 143, 154-156]. The TERT promoter mutation in PTC 
is thus the second most common mutation in addition to the BRAF mutation which is 
regarded as the most common oncogenic event [146]. TERT promoter mutation was 
associated with tumor size, late tumor stage, and was found to be a predictor of metastasis 
and shorter patient survival in thyroid cancer. In addition, similar clinical implications were 
observed in renal carcinoma, glioblastoma and some other types of cancer [142, 157, 158]. In 
conclusion, all these findings indicate the TERT promoter mutation is an important genetic 
alteration in cancer which may serve as a useful biomarker in clinical practice. 
1.4.2 Epigenetic changes of TERT in human cancer 
The TERT promoter region lacks TATA or CAAT boxes but is rich in GC-nucleotides, 
indicating the epigenetic regulation by DNA methylation is involved in transcriptional 
regulation of TERT in normal and cancer cells [159, 160]. 
Promoter methylation is known to be associated with gene silencing, and inactivation of 
TSGs by hypermethylation plays a crucial role in tumorigenesis. However, the available 
literatures on the role of TERT promoter methylation in TERT regulation appear to be 
discrepant in different tumors and cell lines. Some findings showed methylation of the TERT 
promoter increased TERT expression [161], on the contrast, in others studies methylation of 
the promoter region was correlated with TERT silencing [162] [163]. In studies of TERT 
methylation analysis in breast, colon and lung cancer cell lines, TERT expression could be 
regulated via heterogeneous methylation status at specific regions. In the TERT promoter 
spanning a -150 bp to +150 bp region surrounding the transcriptional start site there is little or 
no methylation; however the -600 bp region upstream of the transcription start site is densely 
methylated, which is associated with TERT expression [164]. This study was based on 
immortalized cell lines; therefore more evidence should be obtained from studies of human 
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caner tissues in the future. Although the role of methylation for TERT expression differs from 
cancer to cancer, de novo methylation is acquired during tumorigenesis [162]. 
Histone modification mediated-chromatin remodeling has been demonstrated to involve into 
TERT expression regulation in previous studies [165, 166]. MicroRNAs, deregulated in 
cancer, were first revealed to be involved in TERT regulation in 2008 [167].  
1.4.3 Dysregulation of TERT by transcription factors 
The TERT promoter contains several transcription factor binding sites, and it can be regulated 
at multiple levels in different cellular contexts. So, transcriptional regulation is believed to be 
the dominant mechanisms for controlling TERT expression in human cancer. The 
transcription factors binding to the promoter are divided into subgroups according to their 
regulatory effects. 
1.4.3.1 Positive regulators of TERT transcription 
The c-myc oncogene plays a crucial role in a variety of human cancer via promoting cell 
growth, proliferation and immortalization [168]. It is well known that TERT is a direct target 
of c-Myc; in the core region of the TERT promoter, two E-boxes with the sequence of 5´-
CACGTG-´3 are recognized and interact directly with c-Myc and Max heterodimers [169-
171]. Over-expression of TERT induced by c-Myc is considered as an important mechanism 
of telomerase activation in many types of human cancer [172]. 
Sp1, universally expressed in normal cells, is a general transcription factor binding to GC 
boxes in promoters, enhancers as well as other regulatory regions. It stimulates a variety of 
genes in human [173]. Sp1 is a zinc-finger transcriptional factor, binding to five GC-boxes 
(5´-GGGCGG-3´) in the core promoter region of TERT, and co-operates with c-Myc to 
activate the transcription of TERT [174]. Overexpressed Sp1 increases the transcription of 
TERT, while mutation induced into the GC-box decreases the promoter activity [170].Besides 
cooperating with c-Myc, Sp1 can activate telomerase by interacting with MBD1-containing 
chromatin-associated factor (MCAF1) [175], high-mobility group A2 (HMGA2) [176] and 
nuclear factor of activated T cell (NFAT) in proliferating cells lines and cancer [177]. 
Besides these two crucial transcription factors, hypoxia-inducible factor-1(HIF-1) was 
observed to stimulate TERT transcription via binding to promoter regions in some types of 
cancers [178, 179], and activating enhancer-binding protein-2 (AP-2) binds to the TERT 
promoter to enhance TERT transcription in lung cancer [180]. In addition to transcription 
factors, oncoproteins may stimulate TERT transcription via different pathways: the human 
papillomaviruses (HPV) type-16 E6 oncoprotein binds to E6 associated protein (E6-AP) by 
repressing NFX1, promoting transcription of TERT [181]. RAS, RAF and growth factors 
stimulate TERT transcription via the ERK-MAPK pathway [182]. Estrogen binds to estrogen 
responsive elements in different promoter regions, inducing increased transcription [183]; it 
also up-regulates TERT at the post-transcriptional level [184]. 
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1.4.3.2 Negative regulators of TERT transcription 
Mad1 is a transcription repressor, and the Mad/Max/c-Myc network is essential in cellular 
transformation, differentiation and proliferation [169, 185]. Mad/Max heterodimers 
competitively binds to the E-box in the TERT promoter, repressing transcription of TERT 
[171, 186].  
The transcription factor AP-1 is a heterodimeric protein of Jun and Fos family members. It 
can directly bind to the upstream positions -2000 and -378 of the TERT promoter region, and 
inhibit transcription [187]. 
As a tumor suppressor, p53 regulates many target genes involving in cell proliferation, 
differentiation, senescence and apoptosis. Since its function is inhibited in many types of 
cancer, p53 is essentially a tumor repressor in the context of tumorigenesis [188].TERT is 
inhibited by p53; p53 can prevent Sp1 binding to TERT promoter in vitro, attenuating the 
stimulatory role of Sp1 [189]. The p53-dependent repression also works via p53 binding to 
the core promoter region of TERT, with the cooperation of Sp1 [190].  
Retinoblastoma protein (pRb) is a tumor suppressor which is inactivated in many types of 
cancer [191]. Hypophosphorylated pRb can down-regulate telomerase activity in cancer cell 
lines [192]. 
In addition, Wilms´ tumor 1 suppressor (WT1), PITX1, TGF-β and other transcriptional 
factors and TSGs prevent tumor formation via repression of telomerase [193-195]. 
1.4.4 Alternative splicing of TERT mRNA transcripts 
Alternative splicing of RNA may be both tissue and disease specific, and will generate 
proteins with different functions [196, 197]. It is a common mechanism for gene expression 
regulation in human. The TERT gene is known to be alternatively spliced at different sites, 
producing multiple transcripts [196, 198-200]. Different TERT splicing variants are illustrated 
in Figure 6, and are described below. 
The α-deletion transcript is generated via deletion of 36bp from exon 6 within TERT motif A; 
the deletion does not affect the protein translation, but it can negatively regulate telomerase 
activity and it is the dominant inhibitor [133, 201]. The β-deletion results from a deletion of 
182 bp at exons 7 and 8, along with a 38 bp insertion at exon 4, producing premature 
terminations upstream of essential motifs [202, 203]. The γ- deletion transcript is generated 
via deleting exon 11and do not exhibit any function [200]. The remaining insertion transcripts 
occur at exons 11, 14 and exon 2. The insertion transcripts at exon 11 and 14 produce protein 
truncations at the N-terminal, thereby resulting in non-functional proteins [204]. 
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Figure 6. Different TERT mRNA transcripts generated by alternative splicing. 
In previous studies of other cancers, telomerase activity was shown to depend on the 
existence of full-length TERT gene expression [199, 205, 206]. In conclusion, alternative 
splicing of RNA is an important post-transcriptional mechanism regulating telomerase 
activity. 
1.4.5 Post-translational regulation of telomerase 
Transcriptional regulation of the TERT gene is the dominant mechanism in controlling the 
telomerase activity. However, telomerase activity does not always corresponded to TERT 
expression, suggesting that post-translational modification of TERT protein plays a role in 
modulating telomerase activity. Phosphorylation of TERT is an important way of post-
translational regulation by affecting different serine or tyrosine residues. Protein kinase B 
(PKB) and protein kinase C (PKC) increase telomerase activity via phosphorylating TERT 
catalytic enzyme [207-209]; whereas c-Abl decreases telomerase activity via phosphorylating 
TERT at tyrosine residues [210].  
1.5 TELOMERASE IN THYROID TUMORS 
The morphology of FTA and FTC may be similar, bringing a diagnostic challenge to 
histopathologists; in addition, the lack of predicting factors for the possibility of thyroid 
malignant transformation from adenoma makes treatment choices more difficult [211]. 
Telomerase activation, a promising marker for many types of cancer, has been explored in 
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different types of thyroid tumors [212]. Telomerase activity and TERT expression were 
detected at frequencies varying from 20% to 100% in PTC, and 30% to 100% in FTC and 
ATC [213]. According to previous studies, telomerase is a potential marker for distinguishing 
FTC from FTA, and it could also be used as useful diagnostic marker combined with routine 
cytology examination on FNA [211, 213, 214].  
In addition, TERT expression and TERT promoter mutation have been associated with 
different aggressive clinical characteristics and shorter survival in thyroid cancer patients [79, 
89, 154, 215-217]. The prognostic role of telomerase in thyroid cancer may contribute to the 
improvement of further therapy and patient follow-up.  
In this thesis work, telomerase activation and its regulation in thyroid tumors were explored. 
The results indicate a prognostic value of telomerase in thyroid cancer.  
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to investigate the telomerase activation and its clinical 
implications in thyroid tumors, and to further characterize the molecular genetic background 
of medullary thyroid carcinoma (MTC) in relation to telomerase activation. 
The specific aims of the included papers were: 
• To explore the TERT promoter mutation and its biological and clinical relevance in 
thyroid carcinomas (Paper I). 
 
• To investigate the occurrence of TERT promoter mutation in thyroid follicular tumor 
development and to correlate it with clinical features (Paper II). 
 
• To characterize mechanisms of telomere maintenance in MTC and the relationship to 
clinical features and survival (Paper III). 
 
• To elucidate mechanisms of telomerase activation and the effects on protein 
expression profiles in MTC (Paper IV). 
 
• To identify proteins regulated in relation to RET and RAS mutational status, and to 
investigate protein changes in response to RET signaling pathway inhibition in MTC 
(Paper V). 
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3 MATERIAL AND METHODS 
Different cohorts of thyroid tumor samples and established human cancer cell lines were 
included in this thesis. 
3.1 HUMAN THYROID TUMOR PATIENTS AND TISSUE SPECIMENS 
3.1.1 Human medullary thyroid carcinoma (MTC) (Paper I, III, IV, V) 
Forty-two MTC patients operated at the Karolinska University Hospital, Stockholm between 
1986 and 2010 were included. The diagnosis was based on histopathological examinations 
following the criteria of the World Health Organization classification [40]. Forty-two fresh-
frozen and 19 formalin fixed paraffin-embedded (FFPE) tumors were collected from 
Karolinska University Hospital Biobank. All fresh frozen tissues were snap-frozen in liquid 
nitrogen and then stored in -80 °C for further study after surgery. Tumor cell representativity 
was assessed by histopathological examinations of tumor sections from all tumor samples by 
a histopathologist at the Karolinska University Hospital. The clinical information for these 42 
patients was retrieved from medical records and follow-up was done regularly with basal 
serum calcitonin measurement and clinical examinations. 
3.1.2 Thyroid follicular cell-derived thyroid tumors (Paper I and Paper II) 
Fresh frozen samples from 52 FTCs, 51 PTCs and 20 ATCs were obtained from the 
Karolinska University Hospital Bio bank. In addition, 58 FTAs and 18 AFTAs operated 
between 1986 and 2004 were collected after surgery.  
3.1.3 Post-Chornobyl PTC (Paper I) 
A cohort of 51 patients operated for PTC in Kyiv City Teaching Endocrinology Center, 
Ukraine was studied for comparison in Paper I. All these patients were exposed to radiation 
in connection to the Chornobyl nuclear plant accident in Ukraine in 1986. 
3.1.4 Non-cancerous thyroid tissue (Paper II - Paper IV) 
Twenty-four non-cancerous thyroid tissue samples from patients treated for other thyroid 
tumors than MTC (Study III, IV) and 20 specimens from non-tumorous thyroid glands (Study 
II) were used as references. 
3.2 ESTABLISHED HUMAN CANCER CELL LINES 
3.2.1 ATC cell lines (Paper I) 
The human ATC cell lines U-hth7, U-hth74, U-hth104 and U-hth112, C634W and SW1736 
were obtained from Uppsala University Hospital, Uppsala, Sweden; ARO and KAT-4 were 
purchased from ATCC. The ATC cell lines were characterized in previous studies in our 
group [218, 219]. 
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3.2.2 MTC cell lines (Paper I and Paper V) 
The human MTC cell line TT carrying a RET mutation in exon 11 was purchased from 
ATCC (LGC Standards GmbH, Germany). The MTC cell line MZ-CRC-1 harbouring a 
M918T RET mutation in exon 16 was obtained from Professor Bruce Robinson and Professor 
Stan Sidhu at University of Sydney, Australia.  
3.2.3 Established non-thyroid cell lines (Paper III) 
The human cervical cancer cell line HeLa (ATCC) and the human embryonic kidney cell line 
HEK 293 (Roche, Germany) were included as references. 
All cell lines used in this thesis are listed in Table 1. 
Table 1. Cells lines used in this thesis  
Cell line Cell line Source / Used 
name origin Reference in Paper 
C643W ATC Uppsala University Hospital I 
SW1736 ATC Uppsala University Hospital I 
U-hth 7 ATC Uppsala University Hospital I 
U-hth 74 ATC Uppsala University Hospital I 
U-hth 112 ATC Uppsala University Hospital I 
U-hth 104 ATC Uppsala University Hospital I 
ARO ATC ATCC I 
KAT-4 ATC ATCC I 
MZ-CRC-1  MTC University of Sydney, Australia I and V 
MTC-TT  MTC ATCC I and V 
HeLa Cervial Cancer ATCC II and III 
HEK 293 Embryonic kidney Roche, Germany II and III 
3.3 METHODS IN THIS THESIS WORK 
In this thesis, different methodological approaches have been used for analyses on the DNA, 
RNA and protein levels. The experimental results were evaluated in combination with 
clinical characteristics of the patients. 
GENETIC ANALYSIS OF TERT, RET, RAS AND BRAF 
3.3.1 DNA extraction, RNA extraction and cDNA synthesize (Paper I – Paper 
V) 
DNA was identified in the late 19th century, and its famous double helix structure was first 
described by James Watson and Francis Crick in 1953 and later awarded with the Nobel Prize 
in 1962. The heritable biological information carried by the DNA molecule lies in the liner 
sequence of nucleotides. The basic unit called gene generates RNA by transcription which is 
then translated into protein.  
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Genomic DNA from frozen tissues and cancer cell lines were extracted with DNase® Blood 
& Tissue Kit (QIAGEN, Germany). All frozen tissues were processed by slicing and 
incubated at 56 °C over-night in lysis buffer with RNase A. DNA was isolated and the final 
concentration was assessed by a NanoDrop ND-100 spectrophotometer (Nano Drop 
Technologies, Wilmington, DE, USA). 
Total RNA was extracted from tumor tissues and cancer cell lines with the mirVana miRNA 
Isolation Kit (Applied Biosystems) and then stored at -80 °C. The RNA was quantified and 
quality assessed with a NanoDrop ND-100 spectrophotometer. Complementary DNA 
(cDNA) was synthesized from RNA using random primer (N6) and M-MLV reverse 
transcriptase (Invitrogen).  
3.3.2 Polymerase Chain Reaction (PCR) (Paper I - V) 
PCR is a widely used molecular biological technology that has revolutionized genetic studies 
in both basic and clinical areas. It was developed by Kary Mullis in 1983 and for his 
discovery he was awarded the Nobel Prize in Chemistry in 1993. The method is based on 
thermal cycling including repeated steps of denaturation, annealing and extension, and thus 
allows rapid amplifications of specific DNA regions. The starting material could be genomic 
DNA or cDNA generated from isolated RNA depending on the purpose of the research.  
3.3.2.1 Reverse transcriptase PCR (RT-PCR) 
RT-PCR is commonly used in RNA expression studies. In this method the RNA from genes 
of interest is first converted into complementary cDNA by reverse transcriptase. 
Subsequently, the newly synthesized cDNA is amplified by PCR and the products are 
visualized by agarose gel electrophoresis. 
To explore TERT gene expression in tissues and cell lines, cDNA was synthesized from total 
RNA and subsequently used as template to amplify the TERT gene and β-actin gene. In 
Paper III, RT-PCR was used to verify the correct PCR products and to prepare the template 
for nested PCR.  
3.3.2.2 Nested primer PCR 
As an effective way to increase the specificity of PCR, the nested PCR is divided into two 
rounds. In the first round, the DNA template is amplified using a set of primers spanning the 
target areas; in the second round, the products from the initial amplification reaction are used 
as templates for a different set of primers which anneals closer to the target region. Therefore, 
non-specific fragments will be excluded, and the method can also be used for detecting 
differentially spliced RNA transcripts. 
Nested PCR was performed in Paper III to detect the TERT mRNA splicing variants. In the 
first round the gene amplification, spanning the regions of all splice transcripts, was done by 
RT-PCR. The products were subsequently used as template for a second round of PCR 
reactions, in which a different set of primers was used.  
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3.3.2.3 Quantitative real-time PCR (qPCR) 
qPCR is a rapid and efficient approach to simultaneously amplify specific nucleic acid 
sequences and measure the concentration of its products. There are two main methods to 
detect the amplifications. (1) double-stranded DNA is bonded by non-specific fluorescent 
dyes, which leads to the accumulation of fluorescence intensity corresponding to the increase 
of PCR products during the PCR reaction. SYBR Green is the commonly used dye binding 
double-stranded DNA. (2) A single-stranded DNA template, amplified by a set of primers 
and Taq polymerase, is hybridized with a sequence-specific oligonucleotides probe labeled 
with a fluorescent reporter at the 5´-end and a fluorescent quencher at the 3´-end. The close 
proximity of reporter and quencher inhibits the emittance of the fluorescent signals. However, 
the probe annealed to the template will be degraded by Taq polymerase along with the 
extension of a new DNA strand, permitting fluorescence from the fluorophore. Thus, the 
fluorescence detected by the real-time PCR machine is proportional to the increasing amount 
of products in each reaction. Taqman probe-based assay is the typical example of this 
method. Both SYBR green and Taqman probe assays were used in this thesis.  
To quantify the nucleic acids amplified by qPCR, both relative and absolute quantification 
are applied. For absolute quantification the exact amount of target gene is given by 
comparison with the standard curve, while the relative amount of gene is obtained by 
comparison with an internal reference gene such as a stable expressed house-keeping gene. 
In Paper II and III, the relative expression of TERT in thyroid tissues and cancer cell lines 
was determined by qRT-PCR using Taqman Gene Expression Assays (Applied Biosystems) 
and cDNA synthesized from total RNA as template. 18S rRNA (Hs99999901_s1) was used as 
internal control and the relative gene expression was calculated based on the relative 
quantification method. 
In Paper IV, TERT copy numbers were assessed by a qPCR-based method using Taqman® 
copy number assays (Applied Biosystems). Human RNase P gene which is known to exist in 
two copies in the human diploid genome, was chosen as internal control. The PCR reactions 
included purified genomic DNA from thyroid tissues, two primers, dNTPs, DNA polymerase, 
and two primers with dye-labeled probe: a FAM-dye labeled MGB probe for TERT and a 
VIC-labeled TAMRA probe for RNase P, respectively. The amplifications of TERT and 
RNase P were run in parallel in duplex qPCR reactions. The target copy numbers were 
calculated using a comparative quantification method (∆∆CT): the CT difference between the 
target and the reference genes was compared to the calibrator in two copies. An ABI 7900HT 
Real time PCR System (Applied Biosystems) was used and the copy numbers were 
predicated analyzed using the CopyCaller software (Applied Biosystems). 
3.3.3 DNA sequencing  
The DNA molecule is a large polymer with four different nitrogenous bases forming a linear 
backbone of alternating sugar and phosphate residues. In eukaryotes DNA is found in the 
chromosomes of the nucleus and in the mitochondria. The heritable biological information is 
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replicated at cell division resulting in the same order of nucleotides in the daughter cells as in 
the parental cells. The determination of the order of the DNA sequence in human and other 
species opened the gate to explore the genetic background of normal development and in 
disease.  
Ever since the first gene of Bacteriophage MS2 was sequenced in 1972 by Walter Fires [220], 
there has been ongoing development of techniques for DNA sequencing. Today, 
fluorescence-based sequencing combined with automated analysis methods are widely used 
in basic and clinical research. In this thesis, Sanger sequencing and Pyrosequencing were 
used for various applications. The principles of these two methods are depicted in Figure 7, 
and Figure 8, and described below in details. 
3.3.3.1 Sanger Sequencing 
Frederick Sanger and his colleagues developed a method based on selective incorporation of 
chain-terminating dideoxynucleotides (ddNTPs) in 1977 [221], which brought him the 
second Nobel Prize for Chemistry in his life. Over the past 30 years, Sanger sequencing has 
been widely used and developed; it still plays a crucial role for detection of genetic alterations 
in spite of the introduction of large-scaled, automated sequencing methods in recent years. 
The method requires a single-stranded DNA template, a DNA polymerase and DNA primers, 
deoxynucleotides (dNTPs) and ddNTPs lacking of 3´-hydroxyl group. The failure of 
formation of phosphodiester bonds between two nucleotides will inhibit the DNA 
polymerase, thus the extension of the oligonucleotide chain will stop at the position of 
ddNTPs incorporation. The ddNTPs are labeled with different fluorescent dyes emitting light 
signal at specific wave-lengths, which facilitates the fragments generated by terminator 
ddNTPs visible. The resulting fragments with differentially labeled ddNTPs are separated and 
detected by capillary electrophoresis for the generation of chromatograms and sequence 
analysis.  
In Paper I, II and V, point mutations in hot spot regions of the TERT promoter, RET and RAS 
were detected using Sanger sequencing. After PCR amplifications, the purified PCR products 
were precipitated with ethanol and EDTA, followed by electrophoresis in an ABI 3730 DNA 
analyzer machine. All steps were referring to the instructions in the BigDye Terminator V3.1 
Cycle Sequencing Kit manual (Applied Biosystems).  
The PCR products were sequenced in both directions and results were analyzed with the 
BioEdit Software and by visual inspection of the chromatograms. 
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Figure 7. Illustration of the main principles of Sanger sequencing. 
3.3.3.2 Pyrosequencing 
Pyrosequencing was developed by Pål Nyren and Mostafa Ronaghi at Royal Institute of 
Technology, Stockholm in 1996, and has since then become one of the commonly used DNA 
sequencing methods. It is regarded as the standard technique for quantitative DNA 
methylation analysis and allows for the detection of single strand of DNA when synthesizing 
the complementary strand. The double-stranded DNA is treated with sodium bisulfite, which 
leads to the convention of un-methylated cytosine residues into uracil but leaves methylated 
cytosine unchanged. The bisulfite converted DNA is used for template of PCR amplification 
with biotinylated primers; the biotinylated amplified single strand DNA is then hybridized to 
sequencing primers and incubate with ATP sulfurylase, luciferase, apyrase and DNA 
polymerase, adenosine-5´-phophosulfate (APS) and luciferin. The incorporation of the first 
nucleotide initiates the reaction and then releases pyrophosphate (PPi), which could be used 
to synthesize ATP with APS by sulfurylase, and the synthesized ATP is the substrate of 
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luciferase. The conversion of oxyluciferin from luciferin by luciferase generates light signals 
proportional to the amount of synthesized ATP. The remaining unincorporated nucleotides 
and extra ATP will be removed by apyrase. The generated light will be captured by charged 
coupled devices (CCD) and visualized in the form of a Pyrogram. Thus the intensity of 
individual light signal corresponds to the number of nucleotides incorporated, and the ratio of 
methylated: unmethylated cytosine will represent the density of methylation at each CpG site. 
 
 
Figure 8. Schematic illustration of Pyrosequencing. 
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In Paper IV, the methylation density of the TERT promoter region in MTCs and normal 
tissues was identified by bisulfite Pyrosequencing. In addition, in Paper I the BRAF 1799 
T>A mutation was determined by Pyrosequencing. 
ASSESSMENT OF TELOMERE LENGTH 
Various methods have been developed to detect telomere and measure the length of telomere 
[222-225]. The golden standard and the most reliable tool is Southern blot analysis of 
terminal restriction fragment (TRF). In addition, fluorescence in situ hybridization (FISH) 
and PCR based methods were developed to detect telomeres of individual chromosomes and 
determine the relative telomere length, respectively.  
3.3.4 Southern blot and quantitative Real-time PCR 
Southern blot analysis was invented by Edwin Southern in the mid-1970s and has been 
wildly used for detection of DNA sequence. The method involves separation of DNA 
fragments by electrophoresis, transfer and hybridization to specific probes. First, size-
separated DNA fragments are transferred to a membrane after gel based electrophoresis. 
Second, the DNA fragments on the membrane are hybridized with a labeled probe. Third, the 
bound probe is detected by e.g. a chemiluminescent reagent. 
In Paper III in this thesis, the distribution and absolute telomere length were detected using 
Southern blot analysis of TRF. Purified genomic DNA was cleaved with restriction enzymes 
that only cleave non-telomeric DNA but not telomeric DNA and sub-telomeric DNA. The 
products were separated by gel electrophoresis, transferred to a nylon membrane, and directly 
hybridized to a digoxigenin (DIG)-labeled probe which can only anneal to telomeric repeats. 
The DNA-probe complex was subsequently incubated with Anti-DIG-Alkaline Phosphatase. 
The final light signal representing the TRF was generated by metabolizing the 
chemiluminescent substrate by alkaline phosphatase. The TRF was compared with molecular 
weight markers and the calculation of mean telomere length was based on the density of 
chemiluminescent signals using the Image software. 
In Paper I, II, and III, relative telomere length were assessed by a qPCR-based method 
(described above), including genomic DNA from frozen thyroid tissues, Platinum SYBR® 
Green qPCR SuperMix-UDG (Invitrogen, Germany) and a set of primers for TEL in each 
reaction. A melting curve was generated at the end of amplification to exclude non-specific 
binding between SYBR Green dye and primers. The single copy gene HBG was used as 
internal control. The ratio of CtTEL and Ct HBG was calculated and taken as proportional to 
the mean relative telomere length.  
All the PCR primers used in this thesis work are list in Table 2. 
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Table 2.  Primers used in this thesis.  
  
Forward and Reverse  
Target Description primer sequences (5´-3´)  
Sequencing of RET 
  
RET exon 10 Forward GCGCCCCAGGAGGCTTGAGTG 
Reverse CGTGGTGGTCCCGGCCGCC 
RET exon 11 Forward CCTCTGCCGTGCCAAGCCTC 
Reverse CACCGGAAGAGGAGTAGCTG 
RET exon 15 Forward GACTCGTGCTATTTTTCCTC 
Reverse GCTTCCCAAGGACTGCCTGC 
RET exon 16 Forward AGGGATAGGGCCTGGGCTTC 
Reverse TAACCTCCACCCCAAGAGAG 
Sequencing of RAS   
HRAS1 Forward  ATGACGGAATATAAGCTGGT 
 
Reverse  CTCTATAGTGGGGTCGTATT 
HRAS2 Forward  AGGTGGTCATTGATGGGGAG  
 
Reverse  AGGAAGCCCTCCCCGGTGCG  
KRAS1 Forward  GGCCTGCTGAAAATGACTGAA  
 
Reverse  GGTCCTGCACCAGTAATATGC 
KRAS2 Forward  CAGGATTCCTACAGGAAGCAAGTAG 
 
Reverse CACAAAGAAAGCCCTCCCCA  
NRAS1 Forward  ATGACTGAGTACAAACTGGT  
 
Reverse  CTCTATGGTGGGATCATATT  
NRAS2 Forward TCTTACAGAAAACAAGTGGT 
 Reverse GTAGAGGTTAATATCCGCAA  
TERT expression 
  TERT Forward CGGAAGAGTGTCTGGAGCAA 
 Reverse GGATGAAGCGGAGTCTGGA 
β-actin Forward GCGGGAAATCGTGCGTGACAT 
 Reverse TGGCGTACAGGTCTTTGCGGATG 
Sequencing of TERT 
  TERT Forward CACCCGTCCTGCCCCTTCACCTT 
TERT Reverse GGCTTCCCACGTGCGCAGCAGGA 
Sequencing of BRAF   
BRAF Forward GCTTGCTCTGATAGGAAAATGAG 
BRAF Reverse GTAACTCAGCAGCATCTCAGG 
Telomere length   
Telomere Tel 1b CGGTTTGTTTGGGTTTGGGT-TTGGGTTT 
  
GGGTTTGGGTT 
Telomere Tel 2b GGCTTGCCTTACCCTTACCCTTACCC 
 
 TTACCCTTACCCT 
HBG3 (β-globin)  TGTGCTGGCCCATCACTTTG 
HBG3 (β-globin)  ACCAGCCA-CCACTTTCTGATAGG 
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DETECTION OF ALT-ASSOCIATED PROMYELOCYTIC LEUKEMIA BODIES 
(APBS) 
3.3.5 Fluorescence in situ hybridization (FISH)  
FISH was developed in the 1980s to identify and localize nucleotide sequences. This 
cytogenetic tool utilizes complementary fluorescently labeled probes that bind to the 
sequences in specific chromosome region, and thus may detect and localize sequence targets 
in cells spreads or tissue samples. Quantitative FISH, a significant convenient and fast 
technique, has been used to detect and measure the telomere length for many years. 
In Paper III, the telomeres were detected by FISH analysis in FFPE MTC tissue samples 
(described in details below). 
3.3.6 Immunofluorescence 
Similar to FISH, immunofluorescence is a method to detect and localize molecular markers in 
the cells. Different from the FISH technique, immunofluorescence utilizes a specific antibody 
to target the proteins of interest within a cell sample or a tissue section. The bound antibody is 
then visualized by a fluorescent dye and the protein localization may be observed using a 
fluorescent microscope. 
In Paper III, APBs was detected by using immunofluorescence combined telomere FISH, to 
explore the interaction between PML and telomere. PML was firstly detected in FFPE slides 
using primary anti-PML mouse monoclonal antibody (Santa Cruz), which followed by Alexa 
fluor® 488 Florescent goat anti- mouse secondary antibody (Invitrogen). The Cy3- (5´-
CCCTAA-3´)3 PNA probe (Panagene, South Korea) was hybridized to the fixed slides for at 
least three hours, which was followed by staining with Tro-Pro®-3 iodide (Invitrogen) in 
mounting medium. The colocalization of the PML and telomere was visualized using a LSM 
510 META confocal laser scanning microscope (Carl Zeiss, Jena, Germany). 
PROTEIN ANALYSIS OF TELOMERASE AND TELOMERASE RELATED 
PROTEINS 
3.3.7 Assessment of telomerase activity  
The telomeric repeat amplification protocol (TRAP) was developed by Kim et al in 1994 
[121], and builds on the principle of PCR-based amplification of products generated by 
telomerase. As illustrated in Figure 9, telomerase may elongate the telomeric repeat 
sequences onto the non-telomeric oligonucleotide TS (5´- AATCCGTCGAGCAGAGTT-3´), 
followed by PCR amplification using upstream and downstream primers binding to the 
elongation products. The TS oligonucleotide is labeled by radioactive P or a flurophore, 
which will be detected and visualized using equipment for gel-based or chemiluminescent 
detection.  
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Figure 9. The principle of telomerase activity assessment. 
In Paper II and III, the telomerase activity was assessed using the Telo TAGGGG 
Telomerase PCR ELISA kit (Roche, Germany). Protein extracts from thyroid tissues 
containing telomerase, which will elongate telomeric repeats to biotin-labeled synthetic TS 
primer. This step was followed by PCR amplification. The denatured single-stranded PCR 
product carrying biotin was hybridized to a digoxigenin-labeled probe. The assay involves an 
Elisa reaction by immobilizing the biotin-labeled PCR products onto the surface of a special 
plate, connecting the DIG-labeled probe and peroxidase labeled antibody against DIG. The 
final telomerase activity was determined by calculating the absorbance at different densities.  
3.3.8 Mass spectrometry  
Mass spectrometry (MS) is an increasingly used technology to identify proteins in biological 
substrates using a mass spectrometer. Three methodological variants are known: MALDI-
TOF-MS, SELDI-TOF-MS and LC-MS/MS. In this thesis work, LC-MC/MS was used to 
identify proteins expressed in MTCs. 
Proteins were extracted from tumor tissue samples followed by alkylation with 
iodoacetamide, digestion with trypsin, and iTRAQ labeling. 
 36 
Protein samples were then separated on IPG strips with narrow (pH 3.7 – 4.9) and ultra-
narrow range (pH 4.0 – 4.2), and eluted into 72 fractions per strip. At reversed phase LC-
MS/MS peptides were fragmented to obtain the amino acid sequences, and peptides were 
identified by matching to a database with theoretical spectra from all human proteins.  
In paper IV and V, the protein expression profiling of MTC samples was performed by 
HiRIEF-LC-MS/MS. 
FUNCTIONAL STUDY IN VITRO 
3.3.9 Assessment of cell viability 
Cell viability is a very important biological feature of normal cells as well as cancer cells. 
Nowadays, several commercial assays are available for cell viability measurement. In 
metabolic activity measurements, the absorption of the dye solution is determined by a 
spectrophotometer. An increasing activity of the enzyme lactate dehydrogenase during cell 
proliferation will decrease tetrazolium salts in the surrounding environment of metabolic 
cells, which subsequently forms a formazan dye leading to color change of the media. 
Another commonly used protocol is to detect antigens associated with cell proliferation, such 
as Ki-67 using the MIB1 antibody. 
In Paper III and V, the proliferation of MTCs was assessed by Ki-67 immunohistochemistry, 
and the cell viability of vandetanib-treated MTC cell lines was determined by the method 
based on metabolic activity. 
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4 RESULTS AND DISCUSSIONS 
4.1 TERT PROMOTER MUTATION AND ITS CLINICAL IMPLICATIONS IN 
HUMAN THYROID TUMORS (PAPERS I AND II) 
In 2013, constitutional and somatic mutations in the TERT promoter region, generating 
consensus binding motifs for ETS/TCF, were reported in melanoma by two different research 
groups [139, 140]. Since telomerase reactivation occurs in thyroid cancer, we speculated that 
TERT promoter mutation might be one potential underlying mechanism. In this thesis work, 
TERT promoter mutations were screened for in thyroid tumors and compared with clinical 
characters and patient outcomes in the Swedish and Ukraine cohorts. 
4.1.1 TERT promoter mutation in human thyroid cancer 
4.1.1.1 The TERT promoter mutations in FTC, PTC and ATC 
A panel of follicular cell-originated thyroid carcinomas including 51 PTC, 36 FTC and 20 
ATC in the Swedish cohort were screened for TERT promoter mutation at the hot spot 
positions chr5: 1,295,228 (C228T) and chr5: 1,295,250 (C250T) using Sanger sequencing. 
Totally, 31 tumors (29%) harbored one of these two mutations, of which C228T was found to 
be the dominant form (87%) compared to C250T. In conclusion, 12/51 PTC (24%), 7/36 FTC 
(19%) and 8/20 ATC (40%) exhibited the C228T mutation, while only one PTC, one FTC 
and two ATCs harbored the C250T mutation. No mutations were detected in the Ukraine 
cohort of 51 PTCs. 
In addition, eight ATC cell lines were examined for TERT promoter mutation. The 
sequencing results revealed that the mutation occurred in 6/8 ATC cell lines. Similar to the 
tumor samples, the C228T mutation was more frequent than C250T which was only detected 
in one cell line.  
4.1.1.2 TERT promoter mutation status in MTCs and two MTC cell lines 
Thirty-seven sporadic MTCs and two MTC cell lines were screened for TERT promoter 
mutation at the sites 228 and 250. However, neither MTC tissues nor cell lines exhibited the 
TERT promoter mutation. 
4.1.2 TERT promoter mutations in human thyroid adenomas 
To further clarify the occurrence of TERT promoter mutations in thyroid tumor development, 
we included 58 patients diagnosed as FTA and 18 patients with AFTA in Paper II. The 
C228T mutation was identified in 1/58 FTA (2%) and 3/18 AFTA (17%). A panel of 20 non-
tumorous thyroid tissues was screened as controls, and as expected, no mutation was found. 
 38 
4.1.3 TERT promoter mutation is positively correlated with TERT expression 
in thyroid tumors 
Constitutional and somatic TERT promoter mutations could create a new Ets/TCF 
transcriptional factor binding motif, which increases the TERT transcription level in 
melanoma and other types of cancers [226]. In this thesis, TERT expression and telomerase 
activity were assessed in thyroid adenoma tissues with different TERT promoter mutation 
status.  
All the three AFTAs and one FTA with the C228T mutation showed detectable telomerase 
activity. One of seven FTAs without mutation expressed trace amounts of TERT transcripts, 
and 2/11 AFTAs without mutation exhibited TERT expression while another two exhibited 
trace levels of TERT mRNA expression. The TERT expression was found to be associated 
with telomerase activity in these tumors, and the TERT expression level was significantly 
increased in mutation positive as compared to wild-type tumors (Fisher´s exact test, P = 
0.008). 
4.1.4 The shorter telomere and age- dependent TERT promoter mutation in 
thyroid tumors 
All 13 PTC patients and 7/8 FTC patients with TERT promoter mutation were older than 45. 
In the group of PTC > 45 years, there was a significant difference in age between mutated 
and wild-type cases (P ˂ 0.0001). Furthermore, analysis of a second cohort of young patients 
who had been exposed to radioactivity from the Chornobyl accident, revealed no TERT 
promoter mutation. For FTC, the average age of patients in the mutation-positive group was 
higher than in the wild-type group (P = 0.05).  
These observations suggested that the TERT mutation is age-dependent in PTC. Shorter 
telomeres and telomerase reactivation are important characteristics of many types of tumors. 
It is also well known that: (1) Reactivation of telomerase is triggered by telomere erosion; 
and (2) TERT expression is increased by creating new binding sites for transcriptional factors 
on the mutation sites. To further explore the background of the observed association, 
telomere lengths were determined in relation to TERT promoter mutation status.  
First of all, we observed that the telomere length was not correlated with age in PTC patients 
(correlation coefficient: -0.22; P = 0.127, Pearson correlation).The mean telomere length was 
shorter in TERT promoter mutation positive PTCs compared to the mutation negative group 
(0.873 ± 0.45 and 1.569±0.627; P ˂0.0001). Second, for the subgroup of PTC cases > 45 
years, the mean telomere lengths was shorter in cases with TERT mutation compared to the 
wild-type group (0.873± 0.45 and 1.451 ±0.724; P = 0.028). Importantly, the TERT promoter 
mutation was found to be dependent on shorter telomere in PTC. 
In FTA and AFTA, all cases with TERT mutation were > 45 years, but no significant 
correlation was observed between age and TERT promoter mutation. The cases with a C228T 
mutation had shorter telomeres vs. the wild-type group (3.97±2.17 vs. 5.32±2.95; P >0.05). 
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4.1.5 Association of TERT promoter mutation with other common gene 
mutations in thyroid tumors 
4.1.5.1 BRAF mutation 
The BRAF mutation V600E is a common genetic alteration in PTC, and this mutation has 
been well studied in vitro and in vivo, and identified as an oncogenic event for PTC [51]. 
Given the high frequency of TERT promoter mutation (27%) and BRAF V600E (32/51, 63%) 
in PTC, we explored the possible relationship between the two alterations, however, no 
association was observed between these two genetic events. 
4.1.5.2 RAS mutation 
RAS mutations are highly prevalent in thyroid tumors. In FTA and AFTA activating 
mutations of three RAS genes (HRAS, NRAS and KRAS) have been reported in previous 
studies [227]. In our Swedish cohort of 18 AFTA and 58 FTA, neither HRAS nor KRAS 
mutation was detected. Five cases carried an NRAS mutation at codon 61 including two 
AFTA and one FTA with TERT promoter mutation. The conclusion was that patients with an 
NRAS mutation were prone to harbor TERT promoter mutation. 
4.1.6 Clinical implications of TERT promoter mutations in thyroid tumors 
4.1.6.1 Association of TERT promoter mutation with the progressive disease and poor 
clinical outcome in PTC  
The TERT promoter mutation was significantly associated with cancer metastases (P = 
0.028), as well as with disease survival (overall survival and disease-related survival) of PTC 
patients. The TERT promoter mutation independently predicted the disease-related survival in 
PTC. 
4.1.6.2 Association of TERT promoter mutation with disease outcomes in FTC 
The FTC patients with TERT promoter mutation had a shorter overall survival and disease-
related survival (P = 0.047 and P = 0.025, respectively). Similarly, the patient group carrying 
TERT promoter mutation stratified by age > 45 years tended to have shorter overall and 
disease disease-related survival (P = 0.192 and P = 0.099, respectively). In the multivariate 
model, the presence of TERT promoter mutation significantly increased disease-related death 
risk (P = 0.033). 
4.1.6.3 TERT promoter mutations are prone to occur in thyroid tumor with aggressive 
clinical behavior 
The prevalence of TERT promoter mutation was 50%, 27%, 22%, 17% and 2% in ATC, 
PTC, FTC, AFTA and FTA, respectively; hence the mutation frequency paralleled with the 
aggressiveness of the disease. In agreement with this observation, TERT mutations were rare 
in FTA. The only FTA patient carrying a C228T mutation developed disease recurrence and 
subsequently died from FTC, whereas, FTA patients without mutation did not have detectable 
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recurrence, which might demonstrated that TERT promoter mutation played an important role 
in thyroid malignant transformation.  
In summary, we identified TERT promoter mutation with different incidences in follicular 
thyroid cell-derived carcinomas (PTC, FTC and ATC), as well as in follicular thyroid 
adenomas (AFTA and FTA). Our results revealed TERT promoter mutation in thyroid 
carcinoma, with the characteristic of age and shorter telomere-dependent, could predict 
disease progression and survival. The study of TERT promoter mutation in AFTA and FTA 
demonstrated the presence of potential oncogenic alterations in thyroid pre-malignance. 
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4.2 TELOMERASE REACTIVATION AND TELOMERE MAINTENANCE IN MTC 
(PAPER III) 
The involvement of telomerase in tumor development and its role in diagnosis and prognosis 
of many types of tumors including thyroid follicular cell-derived tumor has been investigated 
in previous studies [79, 125, 211], however, the role and clinical implications were less 
studied. In this thesis, the telomerase activation status in MTC and its clinical significance 
were explored, in addition to biological mechanisms involved in telomere maintenance in 
MTC. 
4.2.1 Reactivation of telomerase in a subset of MTCs 
Forty-two MTCs including 39 sporadic MTC and three MEN 2 cases were included in this 
study. The results revealed that 21/39 (54%) sporadic MTCs displayed TERT mRNA 
expression and corresponding telomerase activity, while the remaining 18 sporadic MTCs, 
three MEN 2 cases and normal thyroid samples showed no detectable TERT expression or 
telomerase activity. In telomerase-positive MTCs, the telomerase activity strongly correlated 
with TERT mRNA expression (r = 0.967; P = 0.01). In conclusion, reactivation of telomerase 
was identified in approximately half of MTCs. 
4.2.2 Association of telomerase activation with clinical characteristics of 
sporadic MTCs 
In the 39 sporadic MTCs, the telomerase reactivation was detected in 12/15 male and in 9/24 
female patients, demonstrating that telomerase activation is more frequent in men than in 
women (P = 0.02). Histopathological and clinical parameters such as tumor stage, 
metastases, lymph node invasion have been used as predictive markers of MTC. Hence, in 
this study, we compared those parameters between the telomerase-positive and negative 
groups. All patients with telomerase activation were in tumor stage III and IV, while only half 
of cases had stage III and IV in telomerase activation negative group. Telomerase activation 
was associated with more advanced stage at diagnosis (P ˂ 0.0001), with MIB-1 proliferation 
index (r = 0.683; P = 0.01) and with larger tumor size (P = 0.027).  
4.2.3 Telomerase activation may predict the clinical outcome in MTC 
Follow-up showed that among the 21 telomerase-positive cases, 13 died and the remaining 
eight were alive with spread diseases. In contrast, all telomerase-negative patients were alive 
at the end of follow-up except one who died of lymphoma. Patients free of disease displayed 
the lowest telomerase activity, while the cases who died of disease showed the highest 
telomerase activity. Meantime, significant differences in TERT expression and telomerase 
activity were observed between cases free of disease and patients with persistent disease, and 
patients with telomerase activation had a shorter survival compared to the telomerase-
negative group. The multivariate analysis showed that the telomerase activation was an 
independent marker for shorter survival in MTC. 
 42 
In conclusion, the telomerase activation was associated with poor clinical outcome and 
aggressive clinical phenotypes. 
4.2.4 Telomere maintenance in MTC 
As the essential structure at the end of chromosome, the telomere can prevent genome 
instability and preserve the chromosome integrity. Telomere DNA consists of tandemly 
repeated sequences, which are eroded gradually along with each cell division. The critically 
short telomere activates the DNA damage response signaling, and triggers the cellular 
senescence or apoptosis in normal cells, thereby avoiding the immortalization of cells. 
Therefore, the capabilities of stabilizing telomeres and thus escape from senescence and 
sustaining proliferation are essential for cancer cells. In this study, we investigated the 
mechanisms of telomere maintenance in MTC. 
4.2.4.1 Detection of shorter telomere lengths in MTCs 
Relative telomere lengths were determined by using real-time based PCR in 42 MTCs and 24 
normal thyroid tissues. The MTCs displayed shorter telomeres as compared to normal thyroid 
tissues (P = 0.0001). The telomere length was also shorter in the telomerase-positive cases as 
compared to telomerase-negative MTCs. 
4.2.4.2 Telomerase activation and the ALT pathway are two main mechanisms for 
telomere maintenance in MTC 
Telomerase is activated in more than 90% of malignancies, and thus becomes the 
predominant mechanism for telomere maintenance in cancer. In MTC, shorter telomere and 
telomerase activation were identified in a subset of MTCs. In addition, ALT-based 
chromosome recombination was detected in some MTCs. Two key features of ALT 
(heterogeneity of telomere and presence of APBs) were observed in most telomerase-
negative cases. 
In summary, two mechanisms for telomere maintenance were identified in MTC. As the 
dominant mechanism, telomerase could be developed as a prognostic marker for MTCs.  
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4.3 MECHANISMS OF TELOMERASE REACTIVATION IN MTC (PAPERS III 
AND IV) 
In the previous study, telomerase activation and its prognostic implications were revealed in 
MTC; however, the mechanisms underlying the activation are not well studied. The 
telomerase ribonucleoprotein complex, consisting of reverse transcriptase, RNA template and 
several proteins, may be regulated by different factors. In MTC, we investigated the 
dysregulation of telomerase using genetic and epigenetic methods and protein expression 
profiling. 
TERT, the rate-limiting component of the enzyme, is well studied in many types of cancer. In 
MTC, we demonstrated that TERT expression was regulated via different mechanisms. 
4.3.1 TERT promoter mutation in MTCs (Paper I) 
Thirty-seven MTCs in our panel of 42 cases were screened for TERT promoter mutation 
using Sanger sequencing, however, neither C228T nor C250T was observed in these MTCs. 
The result is different from the situation in follicular-cell derived thyroid carcinomas where 
the TERT promoter mutation was established as a mechanism of TERT up-regulation and 
telomerase reactivation. Our results suggest that telomerase reactivation in MTC is not caused 
by TERT promoter mutation. 
4.3.2 TERT copy number changes in MTCs (Paper IV) 
Three copies of the TERT gene locus were detected in 5/39 sporadic MTCs (13%). The 
remaining 34 sporadic MTCs and three MEN2 cases revealed two copies of the TERT gene 
locus similar to the 10 normal thyroid samples analyzed for comparison. All five MTCs with 
copy number gains displayed TERT expression and telomerase activity, three of which 
showed high levels of telomerase activity. These five cases all presented with late disease 
stage at the diagnosis. The results showed that TERT copy number gains occur in a subset of 
MTCs and indicate that this alteration is associated with TERT up-regulation and progressive 
disease in MTC. 
4.3.3 TERT promoter methylation in MTCs (Paper IV) 
4.3.3.1 TERT promoter hypermethylation in MTCs 
TERT promoter methylation was quantified at eight CpG sites located 600 bp upstream of the 
translation starting site by Pyrosequencing in MTCs and thyroid tissues. Hypermethylation 
(MetI >10%) was observed in 27 sporadic MTCs and three MEN2 cases; however, the 
normal thyroid sample exhibited low MetI only (below 10%). Taken together, the MTCs 
showed significantly increased TERT promoter methylation levels comparing to normal 
thyroids (P < 0.0001). 
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4.3.3.2 TERT promoter hypermethylation in telomerase reactivated MTCs 
In our cohort, the TERT methylation level was found to be correlated with TERT mRNA 
expression (r = 0.432; P = 0.006) and inversely with the telomere length (r = -0.343; P = 
0.032). MetIs were lower in telomerase-negative MTCs compared to telomerase-positive 
tumors (P = 0.0001). 
4.3.3.3 Association between TERT MetI and clinical characteristics in MTCs 
Comparison of MetIs with the tumor size, patient gender and tumor stage revealed significant 
associations to tumor size. Using the T-classification in the TNM system, higher MetIs were 
observed in tumors with extensive extra-thyroidal growth (T4) as compared to tumors 
classified as T1, T2 and T3 (P<0.05 in all comparisons).  
RET and RAS mutations are common oncogenic events in MTCs, hence, the possible 
association between these mutations and TERT MetI was investigated. Higher MetIs were 
observed in RAS mutated cases (P = 0.031) as well as in RAS and/or RET mutated cases (P = 
0.002) as compared to the respective wild-type cases.  
4.3.3.4 TERT promoter methylation as a candidate prognostic marker in MTC 
The survival was compared by log rank test for MTCs with high MetI above the median of 
52% (for all cases studied) and MetI below the median level. The results were visualized in 
Kaplan-Meier plots which showed shorter overall survival (P = 0.005) and disease-related 
survival (P = 0.007) for MTC cases with high MetI. These observations suggested that TERT 
promoter methylation could be developed into an additional prognostic marker for MTC 
upon verification of the finding in independent tumor series.  
4.3.4 TERT alternative splice variants in MTCs (Paper III) 
In follicular cell-derived thyroid tumors, the TERT promoter mutation has been described and 
identified as one possible mechanism for telomerase activation [79, 143, 146, 155]. In 
addition to this, alternative splicing of TERT has been reported [206]. In thyroid and other 
tumors, the telomerase activity was found to depend on the expression of full-length TERT 
transcript [199, 205]. In our study, three of four TERT alternative splice variants were 
identified in 21 sporadic MTCs with telomerase activation. Seventeen among 21cases 
showed a combination of full-length transcript variants, α- deletion and β- deletion variants; 
one case only exhibited the full-length variant while the remaining six cases showed the β- 
deletion transcripts only. None was detected to have γ- deletion variant. Cases with the full-
length transcript had shorter survival compared to cases where this transcript was not detected 
(P = 0.04). In conclusion, the TERT full-length transcript was associated with the clinical 
outcomes, implying its important role in telomerase functions in MTC, however, telomerase 
activity was not fully dependent of the full-length transcript. 
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4.3.5 Protein expression profiling based on telomerase positive and 
negative in MTCs (Paper IV) 
Using HiRIEF-LC-MS/MS profiling of 14 MTCs a total of 4,321 proteins were identified and 
quantified, and subsequently analyzed in relation to TERT mRNA expression and telomerase 
activation. No obvious grouping of MTCs could be observed in the principal component 
analysis (PCA) model. 
Totally, 240 of the 4,321 quantified proteins showed differential expression between 
telomerase-positive and negative MTCs (P<0.05). After further refinement of interesting 
proteins two enriched pathways were identified: "DNA double-strand break repair by non-
homologous end joining" and "telomere extension by telomerase". XRCC5 (Ku80) was 
present in both of two pathways. Expression of the XRCC5 gene was found to be increased in 
MTCs as compared to normal thyroid tissues (P = 0.007), and it revealed a positive 
correlation to TERT promoter methylation (r = 0.442, P = 0.007). However, no significant 
difference in XRCC5 expression was observed in relation to telomerase activation status.  
In summary, telomerase activation in MTC could be attributable to multiple mechanisms. 
TERT promoter methylation at a specific region could predict disease outcomes. 
Dysregulation of proteins based on telomerase activation status in MTC need further 
clarification. 
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4.4 GENETIC BACKGROUND AND PROTEIN PROFILES IN RELATION TO 
RET AND RAS MUTATIONS IN MTCS (PAPER V) 
Activating RET mutations are frequently detected at certain exons in patients with MTC, and 
RET has been established as a disease-related gene. In addition to this, somatic RAS 
mutations have been documented in thyroid tumors including MTCs. In this study, we 
screened for RET and RAS mutations in a Swedish MTC cohort, and investigated the 
relationship between these genetic events and clinical characteristics of the patients. By 
applying the recently developed HiRIEF-LC-MS/MS methodology for protein expression 
profiling, proteins related to genetic changes were explored in MTC tumor tissues and in two 
MTC cell lines that were treated with vandetanib. 
4.4.1 RET and RAS mutational status in MTCs 
Among 39 sporadic MTCs, somatic RET mutations were detected in 21/39 cases (54%) 
including the mutations M918T, C611S, C634Y, C634W and A883F. The three MEN 2A 
patients all harbored a constitutional mutation in the form of C634G, C634R and L790F, and 
in addition a somatic A883F mutation was detected in one case. 
RAS mutation was detected in 7/41 MTCs (17%), which included the mutations G13R in 
HRAS, G12A in KRAS, Q61R in KRAS and G13R in NRAS. Six of seven RAS mutations 
occurred in RET wild-type cases, which was in agreement with the suggestion of mutual 
exclusivity between RAS and RET mutations. 
4.4.2 Relationship between RET and RAS mutations with clinical features in 
MTCs 
MTCs with a RET mutation were younger at diagnosis compared to wild-type cases (P = 
0.02), and the M918T mutation tended to be associated with advanced tumor stage in MTCs 
(P = 0.122). However, there was no significant difference between RET mutated and wild-
type MTC cases concerning patient outcome. No significant differences for age, gender, 
tumor size and survival regarding RAS mutation in MTCs were found.  
Comparison of protein expression profiles between MTCs with different mutational status 
revealed quite limited sets of proteins that were differentially expressed between mutated and 
wild-type tumors. The corresponding pathway analysis of dysregulated proteins did not 
reveal significant enrichment for specific pathways. This suggested that MTCs that are wild-
type for RET or RAS mutations carry oncogenic events that to a large extent involve similar 
molecular mechanisms. 
4.4.3 Vandetanib decreases cell viability and induces protein expression 
changes in MTC cell lines 
Two MTC cell lines with different RET mutations were treated with vandetanib for 72h, 96h 
until 7 days. Decreased cell viability was observed in both two cell lines. Protein expression 
profiles of two MTC cell lines after 2, 6 and 24 hours of treatment showed that 685 proteins 
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were regulated in response to vandetanib treatment. Nuclear protein 1 (NUPR1) and TP53 
were identified as upstream activated regulators in both cell lines.  
When comparing the proteins regulated by vandetanib treatment of MTC cell lines with those 
quantified in MTC tissues, an overlap of 110 proteins was identified, however this protein set 
could not separate RET mutated and RET wild-type cases at clustering. Six proteins were 
found to be common between the signature of RET regulated proteins and those regulated by 
vandetanib. Among them, nerve growth factor inducible (VGF) was decreased in MTC cell 
lines after treatment, and showed lower expression in MTCs with M918T RET mutation. The 
function of these proteins needed to be clarified further. 
In summary, dominant RET mutations were frequently detected in MTC, in addition, RAS 
mutations occurred at a lower frequency in MTCs. Vandetanib treatment decreased MTC 
cells viability in vitro, and resulted in differential protein regulation. 
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5 CONCLUDING REMARKS  
Telomerase/TERT, as a diagnostic and prognostic marker, has been reported in various tumor 
types. However, the clinical implication and underlying mechanism in thyroid tumors have 
not yet been determined. This thesis aims to explore telomerase activation in thyroid tumors, 
and then to further clarify the molecular background in relation to telomerase activation. 
The general findings are summarized as follows: 
1. TERT promoter mutations occurred in follicular thyroid cell-derived thyroid carcinomas 
with rather high prevalence. The mutation was identified in follicular thyroid cell-originated 
adenomas. TERT promoter mutation could predict thyroid cancer progression and adverse 
clinical outcomes.  
2. Telomerase was activated in approximately half of MTCs, and its activation could serve as 
a prognostic marker for MTCs. 
3. TERT was regulated at the genetic, epigenetic, transcriptional and translational levels in 
MTCs. TERT promoter methylation in MTCs could predict disease outcomes.  
4. Besides telomerase activation, the ALT mechanism was observed in a subset of MTCs 
without telomerase activation.  
5. RET and RAS mutations were detected in MTCs, and were associated with distinct sets of 
regulated proteins.  
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